Phase 3 Trial of Bedtime Treatment, TNX-102 SL, Reaches Half Enrollment
News
The RELIEF Phase 3 trial assessing the safety and efficacy of TNX-102 SL (sublingual cyclobenzaprine) as a nighttime treatment of pain and disturbed sleep due to fibromyalgia has reached half of its ... Read more